微博
加入微博一起分享新鲜事
登录
|
注册
140
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target? https://www.theragnostics.no/publications/l%C3%B8ndalen-2022-fdg/
请登录并选择要私信的好友
300
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target? https://www.theragnostics.no/publications/l%C3%B8ndalen-2022-fdg/
赞一下这个内容
公开
分享
获取分享按钮
正在发布微博，请稍候